Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8469336 | 0.74 | ALOX5 (0.38) | L3MBTL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL38650817 | 0.74 | ALOX5 (0.38) | L3MBTL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL38650932 | 0.74 | ALOX5 (0.38) | L3MBTL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL23531063 | 0.74 | ALOX5 (0.38) | L3MBTL1KDM4EKMT2AALDH1A1 | |
| SCHEMBL3822968 | 0.73 | CYP2C9 (0.51) | L3MBTL1KDM4EGAAKMT2A | |
| SCHEMBL30758065 | 0.73 | ALOX5 (0.40) | L3MBTL1KDM4EGAAMEN1KMT2A | |
| SCHEMBL2774515 | 0.70 | NPC1 (0.51) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL13748372 | 0.70 | ALDH1A1 (0.50) | L3MBTL1ACHEKDM4EMEN1KMT2A | |
| SCHEMBL4668288 | 0.70 | ALDH1A1 (0.40) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL9852555 | 0.69 | L3MBTL1 (0.44) | L3MBTL1ACHEKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-25 | — | — | US | claimed |
| EP-2552905-A1 | B-RAF KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2013-02-06 | — | — | EP | claimed |
| WO-2011117381-A1 | B-RAF KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190286-A1 | B-RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | L3MBTL1 424/4885ACHE 4677/4885KDM4E 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.